Loading...
XETR
FYB
Market cap583mUSD
Jun 27, Last price  
29.70EUR
1D
6.20%
1Q
15.78%
Jan 2017
18.25%
IPO
277.67%
Name

Formycon AG

Chart & Performance

D1W1MN
P/E
—
P/S
7.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.57%
Rev. gr., 5y
16.01%
Revenues
70m
-10.32%
20,00049,2520138,430276,17312,585,01716,924,98719,532,99529,003,53642,993,51733,157,17534,226,93936,613,00042,497,00077,696,00069,674,000
Net income
-126m
L
-191,0000-1,290,00000860,326577,518-4,066,129-1,581,3827,098,615-2,293,287-5,925,705-13,290,00035,992,00075,795,000-125,672,000
CFO
-23m
L+135.79%
0038,6002,159,000-16,651,000-32,166517,000-5,038,400-4,171,19813,298,900-1,506,100-5,208,000-13,541,000-18,994,000-9,848,000-23,221,000
Earnings
Aug 11, 2025

Profile

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
URL
https://www.formycon.com/
IPO date
Dec 20, 2010
Employees
224
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
69,674
-10.32%
77,696
82.83%
42,497
16.07%
Cost of revenue
92,730
77,677
60,225
Unusual Expense (Income)
NOPBT
(23,056)
19
(17,728)
NOPBT Margin
0.02%
Operating Taxes
(18,582)
3,275
604
Tax Rate
17,236.84%
NOPAT
(4,474)
(3,256)
(18,332)
Net income
(125,672)
-265.81%
75,795
110.59%
35,992
-370.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
83,086
70,488
1,763
BB yield
-9.05%
-7.79%
-0.15%
Debt
Debt current
1,496
21,671
21,715
Long-term debt
19,690
16,816
27,594
Deferred revenue
7,594
Other long-term liabilities
164,726
187,690
299,339
Net debt
(172,518)
(155,598)
(239,217)
Cash flow
Cash from operating activities
(23,221)
(9,848)
(18,994)
CAPEX
(1,545)
(21,196)
(26,759)
Cash from investing activities
(1,459)
(17,380)
(37,070)
Cash from financing activities
39,478
44,443
40,855
FCF
(29,533)
(4,067)
(18,195)
Balance
Cash
41,840
27,041
9,820
Long term investments
151,864
167,044
278,706
Excess cash
190,220
190,200
286,401
Stockholders' equity
(34,179)
89,880
356,580
Invested Capital
671,341
630,047
418,719
ROIC
ROCE
0.00%
EV
Common stock shares outstanding
17,287
16,049
13,884
Price
53.10
-5.85%
56.40
-34.80%
86.50
46.61%
Market cap
917,921
1.41%
905,142
-24.63%
1,200,955
84.33%
EV
745,403
749,544
961,738
EBITDA
116,009
1,906
(15,866)
EV/EBITDA
6.43
393.25
Interest
1,089
94
143
Interest/NOPBT
494.74%